Novo Nordisk A/S

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Novo Nordisk A/S sits in the top decile of US sponsors by registered trial count (#81 of 15,742 sponsors by registered trial count).

431 total trials 34 currently recruiting 342 completed later-stage tilt top decile by trial count

Novo Nordisk A/S: 431 sponsored US clinical trials, 34 recruiting.

Novo Nordisk A/S sponsors 431 registered US clinical trials on ClinicalTrials.gov, 34 of them currently recruiting, and 342 completed. 243 of these trials are in Phase 3-4 (later-stage) and 155 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetes Mellitus, Type 2, with 48 trials.

Top-decile sponsor footprint

Novo Nordisk A/S ranks in the top decile of sponsors by registered trial count (#81 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 75/100

342 of 363 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

431 total, page 3 of 9

COMPLETED Phase 3

A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease

NCT05891496

COMPLETED

A Study to Characterize the Prevalence of Overweight and Obesity Among Patients With Established Cardiovascular Disease

NCT05873660

COMPLETED Phase 1

A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers

NCT05790681

COMPLETED Phase 3

A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)

NCT05823948

COMPLETED Phase 1

A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants

NCT05784402

COMPLETED Phase 3

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

NCT05394519

COMPLETED Phase 4

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

NCT05579249

COMPLETED Phase 1

A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose

NCT05689099

COMPLETED Phase 3

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

NCT05649137

COMPLETED Phase 3

A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

NCT05646706

COMPLETED Phase 3

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range

NCT05564117

COMPLETED Phase 3

A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

NCT05514535

COMPLETED Phase 2

A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

NCT05486065

COMPLETED Phase 3

A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes

NCT05478252

COMPLETED Phase 2

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

NCT05442047

COMPLETED Phase 2

Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

NCT05405114

COMPLETED Phase 3

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec

NCT05352815

COMPLETED Phase 1

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity

NCT05369390

COMPLETED Phase 1

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II

NCT05333107

COMPLETED Phase 3

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

NCT05259033

COMPLETED Phase 3

A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors

NCT05306418

COMPLETED Phase 1

A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People

NCT05227196

COMPLETED Phase 3

A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

NCT05053139

COMPLETED Phase 3

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

NCT05013229

COMPLETED Phase 2

A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

NCT05144984

COMPLETED Phase 3

Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis

NCT05064735

COMPLETED Phase 3

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)

NCT05035095

COMPLETED Phase 1

A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets

NCT04817644

COMPLETED Phase 4

A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

NCT05035082

COMPLETED Phase 2

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

NCT05016882

COMPLETED Phase 2

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

NCT04992065

COMPLETED Phase 2

Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes

NCT04982575

COMPLETED Phase 2

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

NCT04969939

COMPLETED Phase 3

Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes

NCT04916470

COMPLETED Phase 3

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)

NCT04880850

COMPLETED Phase 3

A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)

NCT04848480

COMPLETED Phase 3

A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

NCT04865770

COMPLETED Phase 3

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)

NCT04795531

COMPLETED Phase 3

Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity

NCT04788511

COMPLETED Phase 3

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin

NCT04770532

COMPLETED Phase 3

A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT04760626

COMPLETED Phase 3

Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes

NCT04707469

TERMINATED Phase 1

A Study of FT-7051 in Men With MCRPC

NCT04575766

COMPLETED Phase 3

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT04460885

COMPLETED Phase 3

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

NCT04596631

COMPLETED Phase 3

A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

NCT04560998

COMPLETED Phase 1

A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function

NCT04209049

COMPLETED Phase 2

A Research Study Investigating Mim8 in People With Haemophilia A

NCT04204408

COMPLETED Phase 2

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

NCT03847909

COMPLETED Phase 3

A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

NCT04102189

← Previous Page 3 of 9 Next →

Phase Distribution

PhaseTrial count
Phase 1 94
Phase 2 61
Phase 3 220
Phase 4 23

Where Novo Nordisk A/S enrollment is open (later-stage tilt)

34 recruiting of 431 indexed (8% open); 342 completed (79%).

Phase mix: 243 late (III/IV) vs 155 early (I/II) (later-stage heavy).

Top condition: Diabetes Mellitus, Type 2 (48 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Novo Nordisk A/S: open-pipeline peers nationwide

Peers matched on 431 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

Novo Nordisk A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 0%10%20%30% Total trials Recruiting share Novo Nordisk A/SChildren's Hospital of PhiladelphiaUniversity of Illinois at ChicagoVanderbilt UniversityDartmouth-Hitchcock Medical CenterEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Boston Scientific CorporationUnited TherapeuticsHoffmann-La Roche
Novo Nordisk A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Novo Nordisk A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 431 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

What to do with this Novo Nordisk A/S page

431 registered trials is a research-attention snapshot, not an endorsement of Novo Nordisk A/S or any single study.

  • 34 of Novo Nordisk A/S's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Diabetes Mellitus, Type 2 is the condition Novo Nordisk A/S studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetes Mellitus, Type 2 trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Novo Nordisk A/S pipeline card: 431 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.